ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1881

The Utility of Autoimmune Serologies in Recurrent and Chronic Inflammatory Eye Disease

Alexander Wu1, Sulaiman Mapara2, William Messner3, Sunil Srivastava4, Careen Lowder4 and Rula A Hajj-Ali5, 1Internal Medicine, Cleveland Clinic, Cleveland, OH, 2Hospital Medicine, Cleveland Clinic, Akron, OH, 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 4Cole Eye Institute, Cleveland Clinic, Cleveland, OH, 5Rheumatic and Immunologic Disease, Cleveland Clinic, Cleveland, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Serologic tests and uveitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Inflammatory eye diseases such as scleritis and uveitis are associated with systemic autoimmune disease (SAD) and can be the initial manifestation of a concurrent or subsequent SAD. Despite this association, there remains no consensus on the initial diagnostic workup for patients without evidence of systemic involvement.

Methods:

We performed a retrospective review of patients seen at Cleveland Clinic between 2013 and 2014 by the ophthalmology department with a diagnosis of uveitis or scleritis based on ICD 9 and 10 codes. Subjects were included if they had recurrent or chronic uveitis or scleritis based on 2005 SUN working group nomenclature and no diagnosis of SAD prior to the inflammatory eye disease. Charts were further reviewed for any subsequent development of SAD. Sensitivity and specificity analysis was performed based on the following tests ANA, ACE, RF, CCP and ANCA and the associated SAD.

Results:

2351 patients were identified with uveitis or scleritis, of which 545 patients were recurrent or chronic and were included in the analysis. Eighty-five patients (15.6%) were subsequently diagnosed with a systemic autoimmune disease: sarcoidosis (54%), spondyloarthritis (22%), rheumatoid arthritis (13%), systemic lupus erythematous (7%), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (3.5%). Sensitivities of the screening tests are shown below.

screening test

Number of unique patients with screening test ordered at least once

(n=545)

Number of patients diagnosed with SAD

Sensitivity of serologies for diagnosis of SAD in patients with scleritis or uveitis (95% CI)

ANA

232

6 SLE

*

ACE

262

46 Sarcoidosis

0.59 (0.41-0.77)

RF

165

11 Rheumatoid Arthritis

0.5 (0.19-0.81)

CCP

118

11 Rheumatoid Arthritis

0.5 (0.19-0.81)

HLA-B27

175

19 Spondyloarthritis

0.55 (0.25-0.84)

C-ANCA

120

3 ANCA Vasculitis

*

P-ANCA

120

3 ANCA Vasculitis

*

*Due to small sample size, sensitivity was not calculated.

Conclusion:

15% of patients diagnosed with chronic or recurrent autoimmune uveitis or scleritis subsequently developed a systemic autoimmune disease. Laboratory testing such as ANA for SLE, HLA-B27 for spondyloarthritis, RF and CCP for rheumatoid arthritis, C-ANCA and P-ANCA for ANCA associated vasculitis and ACE level for sarcoidosis were not sensitive for screening tests. Therefore, it is inadequate to use laboratory testing alone to guide referral for evaluation of systemic autoimmune disease in patients with chronic or recurrent uveitis or scleritis. Other aspects, such as characteristics of the eye findings and patient symptoms should be evaluated to improve sensitivity.


Disclosure: A. Wu, None; S. Mapara, None; W. Messner, None; S. Srivastava, None; C. Lowder, None; R. A. Hajj-Ali, Abbvie, 8,Novartis Pharmaceutical Corporation, 5.

To cite this abstract in AMA style:

Wu A, Mapara S, Messner W, Srivastava S, Lowder C, Hajj-Ali RA. The Utility of Autoimmune Serologies in Recurrent and Chronic Inflammatory Eye Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-utility-of-autoimmune-serologies-in-recurrent-and-chronic-inflammatory-eye-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-utility-of-autoimmune-serologies-in-recurrent-and-chronic-inflammatory-eye-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology